AEDG raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-27. Anything still debated is marked as such rather than presented as settled.
Literature searches for this compound must account for several spelling variants. Indexing databases contain epitalon, epithalon, epithalone, and AEDG, and relevant records are scattered across Russian-language and English-language journals that do not consistently cross-cite. Early publications describe the parent extract as a mixture of many peptides, whereas later work addresses the single synthetic tetrapeptide. That shift in nomenclature complicates comparison between studies, because extract data and tetrapeptide data are sometimes cited interchangeably. A search strategy omitting the alternate spellings will return an incomplete set of references.
Reported biological findings come mainly from cell culture and rodent experiments. Those studies describe changes in telomerase catalytic subunit expression, melatonin rhythm amplitude, and antioxidant enzyme activity after peptide exposure. Human data are sparse and consist of small trials with limited blinding and inconsistent endpoints. The proposed mechanisms remain hypotheses rather than established facts, and there is no consensus on whether effects observed in animals carry over to people. Independent replication outside the original research groups is limited, which is a recognised gap in the published literature.
Most experimental work has been carried out in cell culture and animal models. Several reports describe changes in telomerase activity and proliferation in cultured cells, while rodent studies have examined lifespan, melatonin rhythm and reproductive endpoints. Human data remain limited, and much of the published clinical material consists of small trials with incomplete reporting of methods and controls. Whether the cell and animal findings translate into measurable effects in people is an open question, and the mechanistic basis of the reported telomerase changes is not fully established.
Discussions in the literature often conflate three distinct entities: the pineal extract epithalamin, the isolated tetrapeptide AEDG, and commercial preparations sold under similar names. Reviews citing older Russian-language studies sometimes omit detail on purity, route of administration and control groups, which makes cross-study comparison difficult. Researchers working with the compound generally note the need for independent replication, standardized enzyme assays, and clearer reporting of peptide identity. These caveats are relevant when weighing claims that appear in secondary sources rather than in primary reports.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic tetrapeptide | Four amino acid residues |
| Residue sequence | Ala-Glu-Asp-Gly | Abbreviated AEDG |
| Approximate mass | 390.35 Da | Monoisotopic, free base form |
| Parent preparation | Epithalamin extract | Derived from pineal tissue |
| Common spelling variants | Epithalon, epithalone, AEDG | Affects literature retrieval |
Residue composition is the property that most cleanly separates verified material from mislabelled samples. Alanine, glutamate, aspartate and glycine appear in that order from the N-terminus, and the two acidic residues sit in the middle of the chain. Because the peptide is short, it can be produced by solid-phase synthesis and characterised by mass spectrometry without ambiguity. Any reported sample whose measured mass departs substantially from 390 daltons is a different compound or a degraded mixture rather than epitalon.
Epitalon is a synthetic tetrapeptide whose four residues are alanine, glutamate, aspartate and glycine, commonly abbreviated AEDG. Its molecular formula is C14H22N4O9 and its monoisotopic mass is near 390.35 daltons. The peptide carries two acidic side chains, so it is neutral to negatively charged in most aqueous buffers. Published reference summaries usually list it under both spellings, epitalon and epithalon, and treat the two names as the same material.
The compound is generally described as a synthetic analogue of a fragment isolated from a pineal gland extract. Researchers associated with the Saint Petersburg Institute of Bioregulation and Gerontology introduced it during the 1980s and 1990s while studying short peptides from animal tissue. The original extract, called epithalamin, is a heterogeneous mixture, whereas epitalon is a single defined sequence. That distinction matters because findings reported for the extract are not automatically findings about the pure tetrapeptide, and claims about broader biological effects remain a separate question from the chemical identity described here.
Laboratory work has examined effects on telomerase activity in cultured cells, on melatonin rhythms in animals, and on markers of oxidative stress. Some experiments report measurable changes while others show none, and the reported findings rest largely on small studies. The absence of large independent trials means the generality of these results is unresolved rather than settled. Review articles occasionally apply the label geroprotector, a term that reflects a research hypothesis about ageing rather than an established clinical finding.
Epitalon is the common name for a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, usually abbreviated AEDG. All four residues are proteinogenic amino acids, and the free peptide has a calculated mass near 390 grams per mole. Because the chain is short and carries no modifications, it is assembled readily by solid-phase synthesis and is distributed mainly as a freeze-dried solid for laboratory work. Catalogue listings use the spellings epitalon, epithalone, and simply AEDG, and the three refer to the same sequence.
In 2024, Meta released a collection of large AI models, including Llama 3.1 405B, which was competitive with less open models. Meta's description of Llama as open-source has been disputed due to Llama's software license, which prohibits it from being used for some purposes, and due to Meta not disclosing the origin of the data used to train the models. DeepSeek released their V3 LLM in December 2024, and their R1 reasoning model on 20 January 2025, both as open-weights models under the MIT license. This release made widely known how China had been embracing using and building more open AI systems as a way to reduce reliance on western software and gatekeeping as well as to help give its industries access to higher-powered AI more quickly. Projects based in China have since become more widely used around the world as well as they have closed at least some of the gap with leading proprietary American models. Since the release of OpenAI's proprietary ChatGPT model in late 2022, there have been only a few fully open (weights, data, code, etc.) large language models released. In September 2025, a Swiss consortium added to this short list by releasing a fully open model named Apertus. In December 2025, the Linux Foundation created the Agentic AI Foundation, which assumed control of some open-source agentic AI protocols and other technologies created by OpenAI, Anthropic and Block. Starting in November 2024, Lightricks began releasing the LTX video models as open weights.
==== Pale or gray ==== Stool that is pale or grey may be caused by insufficient bile output due to conditions such as cholecystitis, gallstones, giardia parasitic infection, hepatitis, chronic pancreatitis, or cirrhosis. Bile pigments from the liver give stool its brownish color. If there is decreased bile output, stool is much lighter in color.
H3C(CH2)3OMs + KSAc → H3C(CH2)3SAc + KOMs H3C(CH2)3SAc + HSMe → H3C(CH2)3SH + MeSAc Thioesters enolize easily as the sulfur atom stabilizes the enol. But the enols are less nucleophilic than ketene acetals, and carbonyl α-substitution reactions occur more slowly. A reaction unique to thioesters is the Fukuyama coupling, in which the thioester is coupled with an organozinc halide by a palladium catalyst to give a ketone.
Many small studies using small doses, often half the recommended dose, have not shown much effect, but these cannot be relied upon to give much information on the more common practice of step-wise therapy and slow dose escalation. Chronic opioid use predictably leads to tolerance, and may do so fairly quickly, in days to weeks. This occurs even with what are considered modest doses, e.g. ≥25mg oxycodone a day. This may result in the patient to need higher and/or more frequent doses of the drug to get euphoric effects, although it may not be a factor in analgesic effects as tolerance to a dose of opioid does not seem related to loss of efficacy. Tolerance is associated with upregulation of μ-receptors, and possibly others. Concentration-dependence adverse effects may vary based on the user's genetic polymorphisms which can alter drug metabolism. Cytochrome P450, notably CYP2D6, but also CYP3A4, is responsible for the metabolism of various opiates to active metabolites and variations in CYP450 activity lead to varying serum drug levels.
Sources: en.wikipedia.org
King was also faculty senior scientist at the Lawrence Berkeley National Laboratory and was program leader for chemical processes in the Energy and Environment Division from 1978 to 1981. He was one of the founders of the Council for Chemical Research in 1981. In 1990, King co-founded the Separations Division of AIChE and served as its first chair.
== Treatment in the future == N-terminal acetylation plays a larger role overall in cell homeostasis and changing one of the NATs has a large impact, mostly due to the vast number of substrates that are subjected to N-terminal acetylation. The mechanism and impact on the proteome level are much needed to be studied, to understand the molecular mechanisms underlying the phenotypes of the affected individuals. There could be many proteins involved in such mechanisms, and this needs to be studied to reveal new angles for improved treatment.
=== Seth Frazier === Seth Jameson Frazier (born May 20, 1984), the oldest of all the four perpetrators, was a registered sex offender who was incarcerated at the time of the murders. He had a prior conviction in 2008 related to 2006 sodomy and rape of a 14-year-old girl and served 24 months in prison. After his release, Frazier reoffended in 2011 and was convicted of burglary and attempted sexual assault of another 14-year-old girl in Onslow County, North Carolina. He received a sentence of 84 to 110 months for first degree burglary, along with an additional term of 17 to 21 months (consecutive) for firearm possession by a felon. Frazier was serving his sentence at the Pasquotank Correctional Institution at the time of the killings.
– vasevine, traveller's joy Clematis virginiana L. – devil's darning needles, Virginia bower Clematis viridiflora Bertol. Clematis vitalba L. – traveller's joy, old man's beard Clematis viticaulis E.Steele – Millboro leather flower Clematis viticella L. – Italian leather flower, purple clematis
In this section, the principal GUT models and their variants are briefly introduced, focusing on their proton decay predictions. For a comprehensive overview of Grand Unified Theories, see the dedicated article. SU(5): introduced in 1974 by Georgi and Glashow, is the minimal choice for unification in a simple group. One SM generation of particles comes from
Sources: en.wikipedia.org
It is based on epithalamin, a peptide-rich preparation obtained from pineal gland tissue and studied in the former Soviet Union. Researchers later identified the tetrapeptide AEDG as a constituent fragment of that material. Modern supplies are produced by chemical synthesis rather than tissue extraction.
No. Epithalamin is a heterogeneous extract containing many peptides, while epitalon is a single synthesised tetrapeptide. Publications sometimes treat findings from the two as equivalent, which is a common source of confusion. Their compositions differ and they are not interchangeable in analytical terms.
Most published work uses cell cultures or rodents because those models are faster and less costly to run. The few human trials that have been reported are small, and several lack control groups or blinding. This restricts what can reasonably be concluded about effects in people.
It is a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, often abbreviated AEDG. The molecule is linear and contains no modified residues, so it is fully described by its sequence.